Pharmaceutical company Elan and its US partner Biogen say Britain's health watchdog has recommended their Tysabri drug to treat a severe form of multiple sclerosis.
The two firms said Britain's National Institute for Health and Clinical Excellence (NICE) had recommended Tysabri as a treatment for highly active relapsing remitting multiple sclerosis.
Tysabri is the first treatment for multiple sclerosis to be recommended for use by NICE.
Elan shares closed up 33 cent at €16.46 in Dublin this evening.
